Zhaoke Ophthalmology, part of Lee's Big Pharmaceuticals, filed for an IPO on the Hong Kong Stock Exchange

In the selection of adaptive disorders, mega-ophthalmology focuses on five major ophthalmological adaptations with large gaps in medical needs in China, including dry eye disease, wet geriatric macular degeneration, diabetic macular edema, myopia and glaucoma.
because of the existence of a variety of pathological processes, the severity of most eye diseases is divided into multiple stages, thus affecting the microenn environment with specific tissue reactions.
, most eye diseases are heterogeneity.
For different adaptations, mega-ophthalmology's development strategy is to select and develop a variety of drug candidates with different mechanisms of action, hoping to give patients flexible treatment options through monotherapy or combination administration.
application for a 23-drug ophthalmology unit has been established to cover most of the major ophthalmological diseases and symptoms affecting the immediate and posterior sections, according to the prospecto filing.
has been favored by many investment institutions since its inception.
June 2019, Mega ophthalmology completed approximately $50 million in round A financing.
November 2020, the company completed another $145 million B round of financing.
the prospect <2> <8>, the company's investors include Singapore Government Investment Corporation, Sorghum Capital, TPG, Zhengshing Valley Capital, Obo Capital and Eyre Eye Hospital, among others.
successful listing on the Hong Kong Stock Exchange, Mega ophthalmology will enter a new stage of development.
s rich pipeline of innovative pharmaceutical products In the product pipeline of M. Ophthalmology, there are 11 innovative drugs, covering dry eye disease, wet geriatric macular degeneration, diabetic macular edema, myopia and other adaptations.
, according to the prospecto, there are eight drugs that have the potential to be candidates for China's "best-in-class" or "first-in-class".
cyclosporine A eye gel cyclosporine A drug is an innovative hydrogel dosage form that spreads faster on the eye surface and stays longer, and is the late core product of M. Ophthalmology.
in a Phase 2 exploratory study of patients with moderate to severe dry eye disease, cyclosporine A-eye gels were given once a day, demonstrating good efficacy and safety.
addition, by eliminating all day-time medication and associated discomforts and inconveniences, cyclosporine A-eye gels are expected to significantly improve patient compliance and quality of life once a night.
currently, MKO Ophthalmology is conducting Phase 3 clinical trials in China to assess the efficacy and safety of cyclosporine A eye gels in patients with moderate to severe dry eye disease, and the trial is expected to be completed in the fourth quarter of 2021.
the company plans to submit a new drug listing application to China's State Drug Administration (NMPA) by the first half of 2022.
RGN-259 RGN-259 is a new therapeutic peptide (thymosin beta 4), which protects tissue and promotes repair and regeneration of eye drops intended for the treatment of moderate to severe dry eye disease.
Ophthalmology has obtained an exclusive license from RegeneRx to develop, produce and sell RGN-259 and other thymosin beta 4-based drugs in Greater China.
Regenerx has completed a Phase 2/3 clinical trial and two Phase 3 clinical trials in the United States.
RGN-259 has a new mechanism of action with the dual effects of corneal repair and anti-inflammatory effect.
studies have shown that the drug is effective quickly on a variety of signs and symptoms.
in a Phase 3 trial completed in the United States, RGN-259 showed statistically significant reductions in eye discomfort and corneal fluorin staining compared to placebo, while also showing good safety.
Program will submit a clinical trial application to NMPA in the second half of 2022 based on the results of Phase 3 clinical trials conducted by RegeneRx.
cyclosporine A/Rebapat eye gel This drug is a proprietary and innovative combination eye gel with a dual mechanism of anti-inflammatory and tear membrane stabilization, which may be more effective in patients who do not respond to exosporine A.
preclinical studies, cyclosporine A/Rebapat eye gel had a significant effect on improving the signs and symptoms of dry eye disease in stable rabbit dry eye disease models.
IC-265 IC-265 is a drop of eye drops composed of highly selective and powerful Syk tyrosine kinase inhibitors with extensive anti-inflammatory effects and general efficacy in reducing allergic conjunctivitis signs.
Ophthalmology corporation obtains an exclusive license from IACTA to develop, manufacture and sell IC-265 in Greater China and several Southeast Asian regions.
, phase 2 clinical trials of IC-265 for the treatment of allergic conjunctivitis have been completed.
Ophthalmology program plans to launch phase 2 clinical trials of IC-265 in China in the first half of 2022.
addition, the company plans to develop IC-265 to treat staphylococcitis.
Ophthalmology Innovative Pharmaceutical Product Pipeline (Screenshot Source: Reference: References) PAN-90806 PAN-90806 is an anti-VEGF preparation for eye drops, which is intended to be developed for the treatment of wet geriatric macular degeneration and diabetic macular edema.
Ophthalmology has obtained exclusive license from PanOptica to develop and commercialize PAN-90806 in Greater China, Korea and several other Southeast Asian regions.
according to the prospectine, PAN-90806 is a small molecular compound with optimum chemical and chemical properties that can be delivered externally.
approved, the drug will provide patients with a convenient and less invasive treatment option, reducing the frequency of injections in the glass of mainstream anti-VEGF therapy while maintaining visual stability.
TAB014 TAB014 is an antibody based on beval bead monoantigen, which is intended to be developed for the treatment of wet geriatric macular degeneration.
beva bead monoantin is a clinically proven anti-VEGF drug.
Ophthalmology has obtained an exclusive license from Dongxuan Pharmaceuticals to commercialize TAB014 in China for the treatment of angiopathic eye diseases associated with angiogenesy.
, TAB014 is currently conducting clinical studies in China on wet age-related macular degeneration.
Phase 3 clinical trial of TAB014 will be launched in the second quarter of 2021.
ZK002 ZK002 is a proprietary protein with a new mechanism of action to inhibit inflammation (i.e. anti-inflammatory effect) and blood vessel leakage (i.e. anti-permeability) to develop the treatment of diabetic macular edema.
anti-penetration and anti-inflammatory properties, ZK002 also has anti-angiogenesic effects.
refore, MKO Ophthalmology believes that ZK002 has the potential to become a basic drug for the treatment of congenital diabetic retinal lesions other than diabetic macular edema (as a monotherapy or combination anti-VEGF preparation).
NVK-002 NVK-002 is a new type of external eye solution for controlling the progress of myopia.
according to the prospectus, NVK-002's proprietary dosage form successfully addresses the instability of low-concentration ato products, which are preservative-free and have a validity period of up to 24 months.
Ophthalmology, which owns exclusive licenses for NVK-002 in Greater China, Korea and several parts of Southeast Asia, plans to file a clinical research application with NMPA in the first quarter of 2021.
other new drug candidates In addition to the above drugs, M. Ophthalmology has a number of innovative candidates, including: ZKY001, intended for the treatment of corneal epithelial defects (CED) eye drops; 270, a fixed-dose compound of IC-265 (Syk tyrosine kinase inhibitors) and antihistamines intended for the treatment of allergic conjunctivitis, and ZK002, a proprietary protein with anti-angiogenesis and anti-inflammatory effects, to develop the treatment of pterosaurs (the main symptoms are tissue/angiogenic and inflammation).
In addition, MKO Ophthalmology also has a pipeline of generic products including more than a dozen products, including bima prostatin, bima prostatin, latatin prostatin, quercetin proseccotin, zuctopolor hydrochloric acid, sodium fluorin and so on.
Zhaoke ophthalmology generic pharmaceutical product pipeline (screenshot source: References.
: The company will spin off Zhaoke Ophthalmology Limited and list it on the main board of the Stock Exchange. Retrieved Dec 18 2020, from .2 Zhaoke Ophthalmology Limited Prospects. Retrieved Dec 18, 2020, from s.3 m. ophthalmology is about to take off on its own! December 18 successfully submitted a prospectus on the Hong Kong Stock Exchange, by the Li's big pharmaceutical company spin-off listing is progressing smoothly! Retrieved Dec 21,2020, from Source: Medical Mission Hills